Following a limited submission
AWMSG advice |
||||
| Status: Recommended | ||||
Teriparatide is recommended for use within NHS Wales as an alternative treatment option for the secondary prevention of osteoporotic fragility fractures in men at increased risk of fracture. Inclusion, exclusion, starting and stopping criteria are the same as those in the NHS England clinical commissioning policy for osteoporosis in men. This recommendation has been endorsed by the All Wales Medicines Strategy Group (AWMSG) and ratified by Welsh Government. This recommendation will be considered for review after three years. This advice replaces the AWMSG recommendation previously issued in November 2008 (AWTTC reference number 306). |
||||
|
||||
Medicine details |
||||
| Medicine name | teriparatide | |||
| Formulation | 20 micrograms/80 microlitres solution for injection | |||
| Reference number | 6561 | |||
| Indication | Treatment of osteoporosis in men at increased risk of fracture |
|||
| BNF chapter | Endocrine system | |||
| Assessment type | Limited | |||
| Status | Recommended | |||
| Scrutiny Panel meeting date | 06/02/2025 | |||
| LOWMAG meeting date | 07/05/2025 | |||
| AWMSG meeting date | 18/06/2025 | |||
| Date of issue | 20/06/2025 | |||
| Further information This advice replaces the AWMSG recommendation previously issued in November 2008 (AWTTC reference number 306). |
||||